Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SCRI-CARB7H3 |
Synonyms | |
Therapy Description |
SCRI-CARB7H3 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) and truncated EGFR (EGFRt), which potentially induce an enhanced antitumor immune response (PMID: 36259971). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SCRI-CARB7H3 | 4-1BBzeta-B7H3-EGFRt-DHFR | SCRI-CARB7H3 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) and truncated EGFR (EGFRt), which potentially induce an enhanced antitumor immune response (PMID: 36259971). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04185038 | Phase I | SCRI-CARB7H3 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | Recruiting | USA | 0 |